Skip to content

The efficacy and safety of minocycline combined with radiofrequency induction of compound lidocaine cream in the treatment of rosacea

The efficacy and safety of minocycline combined with radiofrequency induction of compound lidocaine cream in the treatment of rosacea

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300074594
Enrollment
Unknown
Registered
2023-08-10
Start date
2023-08-14
Completion date
Unknown
Last updated
2023-08-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

rosacea

Interventions

Minocycline combined with radiofrequency induction of compound lidocaine cream:Radiofrequency induction of compound lidocaine cream
Minocycline combined with radiofrequency induction of physiological saline:Radiofrequency induction of physiological saline

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Patients with rosacea diagnosed according to the Guidelines for the diagnosis and treatment of rosacea in China (2021 edition) and accompanied by obvious facial conscious symptoms, including itching, burning, tingling and swelling. 2. Age range: 18-60 years old. 3. Participants who are informed of and have signed the informed consent form for this study.

Exclusion criteria

Exclusion criteria: 1. Having other skin diseases on the face, such as acne, melasma, freckles, and seborrheic dermatitis, may affect the judgment of the test results. 2. Individuals who are allergic to the investigational drug and matrix or have a hypersensitive constitution. 3. Pregnant or breastfeeding women or those planning to become pregnant. 4. Patients who have received drug treatments within the last month, such as pregabalin, NSAIDS and antihistamines. 5. Patients who have used calcineurin inhibitors on the face within 3 months. 6. Patients who have received any other chemical, physical, or medication treatment on the face within the last month. 7. Patients who have received facial injection or surgical treatment within 2 months. 8. Patients with immunodeficiency diseases.

Design outcomes

Primary

MeasureTime frame
Conscious symptom relief rate;

Secondary

MeasureTime frame
IGA score;Dermatology life quality index;Rosacea life quality index;Dermoscopy;Red zone score of VISIA;Transepidermal Water Loss;Stratum Corneum Hydration;

Countries

China

Contacts

Public ContactXiang Wen

Department of Dermatology, West China Hospital, Sichuan University.

xiangwen_wcums@163.com+86 153 5120 0113

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026